Form 4: Castle Biosciences CEO Derek Maetzold Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Derek Maetzold, CEO of Castle Biosciences, executed multiple sales of common stock on September 3rd and 4th, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Derek Maetzold, the President and CEO of Castle Biosciences, sold shares of common stock on September 3rd and 4th, 2024.
- The sales were executed under a Rule 10b5-1 trading plan adopted on December 5, 2023.
- On September 3rd, shares were sold at a weighted-average price of $30.048.
- On September 4th, shares were sold at a weighted-average price of $30.024.
- The transactions involved both direct holdings and indirect holdings through various trusts, including The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, and several Maetzold 2018 Remainder Trusts.
- Following the reported transactions, Maetzold continues to hold a significant number of shares both directly and indirectly.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to insider trading. It doesn't inherently convey positive or negative sentiment, as it simply reports transactions executed under a pre-arranged plan.
Risks
- Sales by insiders, even under 10b5-1 plans, can sometimes be perceived negatively by the market.
Industry Context
Insider trading activity is common and closely monitored, especially in the biotech industry. Rule 10b5-1 plans are designed to allow insiders to sell shares without being accused of trading on non-public information.
Stakeholder Impact
- The stock sale may have a minor impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 2023-12-05 | Date of adoption of the Rule 10b5-1 plan |
| 2024-09-03 | Date of first reported transaction |
| 2024-09-04 | Date of second reported transaction |
| 2024-09-05 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.